STAG3L2

Across TCGA pan-cancer cohorts, STAG3L2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated STAG3L2 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher STAG3L2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated STAG3L2 expression acts as an unfavorable survival marker.

HNSC and READ are the cancer types where STAG3L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.128	0.710	.001	36	view →
READ	OS	Median	All	0.183	0.828	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

STAG3L2–HNSC (DFS)

Open the HNSC breakdown →